CA-MAWI-DNA-TECHNOLOGIES
25.4.2022 15:04:05 CEST | Business Wire | Press release
Mawi DNA Technologies (Mawi), a biotechnology company focusing on the development of innovative technologies for biosampling, announces that Prime Discoveries has successfully developed CovidDetect™, a rapid isothermal amplification diagnostic assay for detecting SARS-CoV-2. Without the need for RNA extraction and purification, the sample result occurs in less than 30 minutes. The assay uses Mawi’s new iSWAB Microbiome-EL (Extraction-Less) sample collection technology. This allows RNA release from the sample and maintains stability, protecting it from degradation and allowing room temperature storage and transport.
Prime Discoveries recently received CE IVD marking for CovidDetect™ and plans to pursue FDA 510K approval soon. Clinical results from Prime CovidDetect™ has been peer reviewed and recently published in PLOS ONE under “A Rapid, Specific, Extraction-Less, and Cost-Effective RT-LAMP Test for the Detection of SARS-CoV-2 in Clinical Specimens .” The CE marking allows deployment of a solution to countries in Africa and Asia where rapid, inexpensive diagnostics for various infections with minimal technical expertise and equipment infrastructure is highly required.
Prime CovidDetect™ leverages Mawi’s unique iSWAB Microbiome-EL sample collection buffer with Prime Discoveries’ patented Loop AMPlification (LAMP) technology. This allows isothermal nucleic acid amplification removing the need for expensive thermal cycling equipment required for PCR. The Extraction-Less protocol bypasses the expensive and complex nucleic acid extraction and purification step, saving 60-90 minutes of sample processing time needed for PCR.
Arun Manoharan, Ph.D., Chief Science Officer at Prime Discoveries, said, “The COVID pandemic has shown that there is a big need for rapid diagnostic assays. Prime Discoveries aims to build a portfolio of solutions which can provide results in under 45 minutes with minimal laboratory, reagent and technical skill requirements. This is ideal for point of care testing in rural neighborhoods, mobile testing, border points of entry and clinical locations with minimal infrastructure. Our work with COVID has shown stable performance of the Mawi iSWAB Microbiome-EL for hundreds of clinical samples with similar or superior performance to RT-PCR solutions. Samples have been stable for more than two weeks with minimal RNA degradation along with high compatibility with our isothermal nucleic acid amplification techniques.” He added, “Our partnership with Mawi enables Prime Discoveries to develop room temperature sampling with Extraction-Less capabilities for our rapid diagnostic solutions in many areas. These include influenza, chlamydia, gonorrhea, trichomonas, HBV, HCV, HPV, TB, herpes, syphilis, etc. We are excited to partner with Mawi for future products empowering customers to test thousands of patients rapidly for various infections including respiratory, gastrointestinal, sexually transmitted pathogens and those with anti-microbial resistance.”
About Prime Discoveries
Prime Discoveries develops rapid, novel diagnostics for emerging pathogen infections with a focus on cost effective, massively scalable and easily automatable assays. Founded in NYC in 2017, Prime’s scientists have extensive backgrounds in microbiology, computational biology, lab automation and AI from Genentech, Cooper Genomics, Recombine, Phosphorus, and NYU. Prime is advised by leading experts in the fields of genomics and public health including Dr. George Church and New York University. Prime is supported by academic institutions, venture capital firms and angel investors including New York University, Charles Zegar (Bloomberg), Esther Dyson (23 & Me), BoxGroup, Akron Fusion Ventures, Beresford Ventures, Cannonball Capital, Liquid 2 Ventures, Francois Nader (Moderna, Acceleron, Shire), Unshackled Ventures, Doberman Forward, and others. For more information, visit www.primediscoveries.com .
About Mawi DNA Technologies
Mawi DNA Technologies, founded in 2013, has developed and commercialized the iSWAB technology, an innovative system for collection of biosamples. Mawi’s mission is to uphold sample integrity from anywhere in the world at room temperature, enabling true sample diversity across any geography or population segment. At Mawi, The Future of Biosampling is Here™. For more information, visit http://www.mawidna.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220425005323/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
AI Meets Traditional Culture: Huangshan Captures Widespread Attention at ITB Berlin7.3.2026 10:22:00 CET | Press release
Huangshan, one of China’s most iconic scenic destinations, drew significant attention at this year’s ITB by presenting a compelling fusion of traditional Chinese culture and cutting-edge artificial intelligence under the slogan “The world of Huangshan is for the world.” This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260307909978/en/ International visitor admires Huangshan cultural and creative exhibits at the Huangshan stand during ITB Berlin. Located in eastern China’s Anhui Province, Huangshan is famed for its “Five Natural Wonders” — fantastic pines, grotesque rocks, sea of clouds, hot spring and winter snow. The mountain is widely regarded as one of China’s greatest mountain landscapes. It is also a rare natural heritage site that simultaneously holds multiple international designations, including UNESCO World Cultural and Natural Heritage status, a UNESCO Global Geopark and a World Biosphere Reserve. At ITB, the Huangsh
Incyte Announces the European Commission Approval of Zynyz® (retifanlimab) for the First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)6.3.2026 22:42:00 CET | Press release
- Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) is the first systemic treatment for adult patients with advanced SCAC in Europe- The EC approval is based on results of the POD1UM-303 study which showed that adult patients with advanced SCAC achieved significantly improved progression-free survival with Zynyz in combination with carboplatin and paclitaxel as a first-line treatment compared to chemotherapy alone.1 Incyte (Nasdaq:INCY) today announced that the European Commission (EC) has approved Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) for the first-line treatment of adult patients with metastatic or with inoperable locally recurrent squamous cell carcinoma of the anal canal (SCAC). “The EC approval of Zynyz marks an important step forward for patients with advanced SCAC, a rare cancer for which meaningful treatment advances have not occurred in several decades,” said Bill Meur
Dfns Launches Payouts6.3.2026 21:27:00 CET | Press release
Dfns today announced the launch of Payouts, a new API enabling institutions to convert stablecoins to fiat and route payouts across multiple bank accounts while keeping wallet-level governance and controls in place. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260305327930/en/ Convert stablecoins to fiat and settle payouts to bank accounts in 94 countries, today. Solving the problem of single-rail off-ramps Today, most fintechs and institutions still hard-wire a single payout provider into their stack, or rely on vertically integrated models that bundle routing, pricing, custody, and settlement together. That approach may be convenient early on, but it creates structural problems at scale: weak price discovery because there is no competitive pressure on margins, limited auditability because routing decisions are opaque, and operational fragility because a single provider degradation in any corridor requires architectural i
Klarna Group Plc Clarifies Mechanics of March 9 Lock-Up Expiration6.3.2026 20:23:00 CET | Press release
Klarna Group plc (NYSE: KLAR) today issues the following clarification to ensure investors and market participants have accurate information regarding the mechanics of its lock-up expiration on March 9, 2026, the processes required before pre-IPO shares can be traded on the NYSE, and the prior liquidity opportunities already available to shareholders. This release contains only factual descriptions of the Company's share structure and applicable processes. It does not constitute guidance or a projection of any kind regarding future trading volumes, share price, or the intentions of any shareholder and speaks only as of the date of this press release. 1. 335 million locked-up shares — but two different categories Of the 378 million total ordinary shares outstanding, approximately 335 million are subject to lock-up restrictions expiring March 9, 2026. However, these shares fall into two distinct categories governed by separate sets of regulations. A. 159 million shares (48% of locked-up
Lone Star Funds Announces Agreement to Acquire the Capsules & Health Ingredients Division of Lonza Group AG6.3.2026 18:30:00 CET | Press release
Lone Star Funds (“Lone Star”) today announced that an affiliate of Lone Star Fund XII, L.P. has entered into a definitive agreement to acquire the Capsules & Health Ingredients (“CHI”) division of Lonza Group AG. As part of the transaction, Lonza will retain a 40% equity position in the business. Headquartered in Basel, Switzerland, CHI operates globally across the Americas, Europe and Asia Pacific. The business comprises three segments: Hard Empty Capsules: leading global manufacturer of gelatin and plant-based capsules offering a broad range of innovative solutions for pharmaceutical and nutraceutical customers. Dosage Form Solutions: end-to-end development and manufacturing platform serving nutraceutical and pharmaceutical customers. Health Ingredients: provider of branded, science-backed nutrition ingredients serving joint health, energy and active lifestyle markets. Lone Star believes CHI is a high-quality, globally recognized platform with strong technical capabilities, different
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom